Kopran Ltd

Kopran Ltd Share Price Today: Live Updates & Key Insights

Get insights on Kopran Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Kopran Ltd Share Price Chart

KOPRAN at 18 Aug 2026 03:23 PM Pharmaceuticals

201.64 +1.93(+0.97%)

Lowest Today 199.51

Highest Today 208.50

Today's Open 201.69

Prev. Close 199.71

52 Week High 219.00

52 Week Low 107.00

Kopran Ltd Fundamentals

Traded Volume: 2,15,013

Market Cap(Cr): 973.63

Avg Traded Price 203.07

1 Year return 28.24%

Upper Circuit 208.5

Lower Circuit 199.5

P/E TTM 39.00

P/B Ratio 1.819

Traded Value(Cr) 433.55

EPS TTM 5.174

Book value/Share 109.820

Dividend Yield 1Y 2.97%

Kopran Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Kopran Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Kopran Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W +13.47%

1M -0.98%

3M +22.07%

1Y +28.24%

YTD +31.79%

Kopran Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Kopran Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 1.83L

Day Before Yesterday 1.47L

1W Avg 1.59L

1M Avg 1.29L

3M Avg 5.92L

Kopran Ltd Technical Details

Kopran Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 195

Support 2 190

Support 3 187

Pivot Point : 197

Resistance 1 202

Resistance 2 205

Resistance 3 210

Kopran Ltd Corporate Actions

Kopran Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Kopran Ltd’s capital allocation strategies.

All

Ex-Date 11-Aug-2026 Type D Description 3.00/share@30.00% Record Date 11-Aug-2026 Ratio 30.00

Ex-Date 04-Sep-2025 Type D Description 3.00/share@30.00% Record Date 04-Sep-2025 Ratio 30.00

Ex-Date 02-Sep-2024 Type D Description 3.00/share@30.00% Record Date - Ratio 30.00

Ex-Date 07-Sep-2023 Type D Description 3.00/share@30.00% Record Date - Ratio 30.00

Ex-Date 04-Aug-2022 Type D Description 3.00/share@30.00% Record Date - Ratio 30.00

Ex-Date 05-Aug-2021 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00

Ex-Date 05-Nov-2020 Type D Description 1.50/share@15.00% Record Date 07-Nov-2020 Ratio 15.00

Dividends

Announcement Date 11-Aug-2026 Ex Dividend Date 11-Aug-2026 Dividend(%) 30

Announcement Date 04-Sep-2025 Ex Dividend Date 04-Sep-2025 Dividend(%) 30

Announcement Date 02-Sep-2024 Ex Dividend Date 02-Sep-2024 Dividend(%) 30

Announcement Date 07-Sep-2023 Ex Dividend Date 07-Sep-2023 Dividend(%) 30

Announcement Date 04-Aug-2022 Ex Dividend Date 04-Aug-2022 Dividend(%) 30

Announcement Date 05-Aug-2021 Ex Dividend Date 05-Aug-2021 Dividend(%) 15

Announcement Date 05-Nov-2020 Ex Dividend Date 05-Nov-2020 Dividend(%) 15

Bonus

No Bonus has been declared by KOPRAN

Splits

No Split has been declared by KOPRAN

Others

Rights No Rights has been declared by KOPRAN

Kopran Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Kopran Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Kopran Ltd's relative performance and valuation against major competitors.

Stock Name Bajaj Healthcare Ltd ₹322.10 (-0.29%) M. Cap (Cr) 10.84 1 Yr Return (%) -27.54% P/E (TTM) 61.58 PB Ratio 2.04

Stock Name Remus Pharmaceuticals Ltd ₹898.80 (-0.94%) M. Cap (Cr) 10.59 1 Yr Return (%) -1.91% P/E (TTM) 28.63 PB Ratio 3.02

Stock Name Sigachi Industries Ltd ₹29.54 (+12.11%) M. Cap (Cr) 11.29 1 Yr Return (%) -4.52% P/E (TTM) 44.53 PB Ratio 2.16

Stock Name Kopran Ltd ₹201.64 (+0.97%) M. Cap (Cr) 9.74 1 Yr Return (%) +28.24% P/E (TTM) 39.05 PB Ratio 1.84

Stock Name Themis Medicare Ltd ₹106.98 (+2.78%) M. Cap (Cr) 9.85 1 Yr Return (%) +2.93% P/E (TTM) 24.65 PB Ratio 2.47

Stock Name Bharat Parenterals Ltd ₹1280.00 (-2.07%) M. Cap (Cr) 8.82 1 Yr Return (%) -11.59% P/E (TTM) -57.32 PB Ratio 2.74

Stock Name Wanbury Ltd ₹255.10 (+1.76%) M. Cap (Cr) 8.92 1 Yr Return (%) -1.92% P/E (TTM) 15.92 PB Ratio 6.16

Kopran Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Kopran Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2026 29.66 Mar 2025 23.30 Mar 2024 34.96 Mar 2023 16.87 Mar 2022 -37.81

PARTICULARS Investing Activities Mar 2026 -30.08 Mar 2025 -15.41 Mar 2024 -6.27 Mar 2023 10.05 Mar 2022 -100.26

PARTICULARS Financing Activities Mar 2026 -18.53 Mar 2025 5.64 Mar 2024 -24.08 Mar 2023 -26.13 Mar 2022 138.00

PARTICULARS Net Cash Flow Mar 2026 -18.95 Mar 2025 13.53 Mar 2024 4.61 Mar 2023 0.79 Mar 2022 -0.07

Kopran Ltd Shareholding Pattern

This shows the ownership breakdown of Kopran Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 44.42%

Public 55.06%

Other Institutions 0.0%

FII 0.51%

Mutual Funds N/A%

About Kopran Ltd

Kopran Limited was incorporated on April 26, 1958. The Company was promoted by the Somani group and is a group company of Parijat Enterprises. Company operates in two distinct business verticals. Company specialise in developing and manufacturing Penicillin and non-penicillin-based drugs. Leveraging cutting-edge technology, it manufactures highquality finished dosage drugs that adhere to international requirements. Kopran is one of the key contributors in the manufacturing and sale of diverse active pharmaceutical ingredients and advanced intermediates. The range of APIs manufactured by the Company includes Sterile Cephalosporins and Carbapenems. The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility.Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities. In 1995, the company was awarded the Quality Excellence award by the Indian Drug Manufacturers Association. Kopran's high growth rate in exports has been recognised by a number of awards from CHEMEXCIL and the Ministry of Commerce.The company launched new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps and Amyn Dry Syrup. Kopran entered into a joint venture with M/s Industrial Promotion Services Ltd to take over a running unit viz Kampala Pharmaceuticals Industries Ltd in Uganda.The company has been ranked as amongst the top few fastest growing companies in India(ORG Marg-June 2000). It closed down its manufacturing facility at Saki Naka, Andheri, Bombay. Globalpharma, a joint venture with Dubai Investments Corporation started commercial production in the first quarter of 2002.The company has increased its installed capacity of Liquids by 3.00 lakhs of Litres during 2001 and consequent of this capacity expansion the total installed capacity has gone up to 12.00 lakhs of Litres.The company has also increased its installed capacity of Tablets & Capsules by 270 crores(Nos) and the total capacity has gone up to 1080 crores(Nos).In Feb. 2001, Kopran tied up with E-Merck for co-marketing a new anti-inflammatory drug, Rofecoxib, in India. Rofecoxib is one of the fast-moving non-steroid anti-inflammatory drugs (NSAID), has been launched in the international market. The Company also launched Cholestat (Atorvastatin - a cholesterol reducer) and further gave co-marketing rights for Atorvastatin to E-Merck (India). The company had launched new products in therapeutic groups like Asthma,Cardiology,Diabetes and Lifestyle products during 2003.The company has obtained approval from European Directorate for Quality of Medicines(EDQM) in September 2003. Upgradation of Formulation Manufacturing facility took place to meet with the latest International Regulatory Norms.The United Kingdom Medicines and Healthcare Products Regulatory Agency(UK MHRA) is expected to inspect the facilities in the first quarter of 2004.Kopran Pharmaceuticals Ltd., the Company marketing the SMYLE brand of products was merged into the Company effective from 1st March, 2005. The Company introduced two new bulk drugs viz. Pregabalin and Cefditorin during the year 2007. The Company during the FY 2014-15 sold the Active Pharmaceuticals Ingredients (API) business on slump sale basis to its subsidiary Kopran Research Laboratories Ltd. at a consideration of Rs 110 Crores on 30th March, 2015. Similarly, the Consumer Care Division was sold w.e.f 1 April 2015.In FY 2023, the Company filed process patent applications for Nitroxoline in India, the EU and China. It received process patent for Nitroxoline in India and registered Nitroxoline in Germany. 14 new products launched during the year 2023. The Company further undertook the expansion of the multi-product plant at the Mahad facility to manufacture new molecules in 2024. The Scheme of Amalgamation between Kopran Laboratories Limited and the Company has been approved in the Board Meeting held on March 20, 2025.

Executive Vice Chairman

Surendra Somani

Registered office Parijat House 1076, Dr E Moses Road Worli, Mumbai, Maharashtra, 400018

FAX :91-22-43661111

Background

Incorporation Year 1958

Face Value ₹10.00

Market Lot 1

Kopran Ltd Latest News

VIEW MORE NEWS

FAQs on Kopran Ltd